BACKGROUND
The thyroid gland is responsible for making the thyroid hormones, T3 and T4. Hypothyroidism, or an underactive thyroid, is a common medical condition that requires replacement of the thyroid hormones. Levothyroxine (synthetic T4) is the most commonly prescribed form of thyroid hormone treatment. However, there has been growing interest to understand the risks and benefits of also replacing T3, along with T4, in patients with hypothyroidism as some patients do not feel well on T4 alone. Although more data are needed regarding the potential concerns of T3, it is thought that approximately 5–7% of T3 and 93–95% of T4 may be a safe ratio for those who desire T3. Currently, T3 and T4 treatments are available as either synthetic or animal-derived formulations. The animal-derived products (desiccated thyroid extract) contain approximately 25% T3 and 75% T4 in a single pill. Synthetic T3 and T4 are only available as two separate prescription pills.
Thermal inkjet printing is a form of 2D printing which may have interesting uses within the pharmaceutical industry. It can deliver very precise amounts of a one or more substances through the use of a special type of printing. Thus, it can potentially produce a highly personalized combined single pill of synthetic T4 and T3 (in any desired ratio of the two thyroid hormones). This study reports the potential use of 2D-printed T4 and/or T3 gel films as a novel, futuristic form of personalized thyroid replacement therapy.
THE FULL ARTICLE TITLE:
Alomari M et al. Printing T3 and T4 oral drug combinations as a novel strategy for hypothyroidism. Int J Pharm 2018 Jul 29;549(1-2):363-369.